Moreover, acquired resistance toward distinct HSP90i (exhibiting different binding modes) was studied in BCR-ABL1+ leukemia cells, highlighting the involvement of heightened HSP90α or MDR1 levels in mitigating the efficacy of HSP90 inhibition. Here, BCR is linked to leukemia.